Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients - DTU Orbit (05/11/2018)

**Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients**

Background: Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients. Methods: The study included a total of 82 recurrent glioblastoma patients treated with bevacizumab combination therapy whom were both response and biomarker evaluable. Gene expression of tumor tissue was analyzed by using a customized NanoString platform covering 800 genes. Candidate gene predictors associated with response were analyzed by multivariate logistic and Cox regression analysis. Results: Two genes were independently associated with response: Low expression of angiotensinogen (2-fold decrease in AGT; OR = 2.44; 95% CI: 1.45-4.17; P = 0.0009) and high expression of a HLA class II gene (2-fold increase in HLA-DQA1; OR = 1.22; 95% CI: 1.01-1.47; P = 0.04). These two genes were included in a model that is able predict response to bevacizumab combination therapy in clinical practice. When stratified for a validated prognostic index, the predictive model for response was significantly associated with improved overall survival. Conclusion: Two genes (low angiotensinogen and high HLA-class II expression) were predictive for bevacizumab response and were included in a predictive model for response. This model can be used in clinical practice to identify patients who will benefit from bevacizumab combination therapy.

**General information**

State: Published
Organisations: Department of Systems Biology, Center for Biological Sequence Analysis, Rigshospitalet, Hvidovre Hospital, University of Copenhagen
Number of pages: 9
Pages: 1160-1168
Publication date: 2016
Peer-reviewed: Yes

**Publication information**

Journal: Molecular Oncology
Volume: 10
Issue number: 8
ISSN (Print): 1574-7891
Ratings:
BFI (2018): BFI-level 1
Web of Science (2018): Indexed yes
BFI (2017): BFI-level 1
Scopus rating (2017): CiteScore 5.17 SJR 2.526 SNIP 1.119
Web of Science (2017): Impact factor 5.264
Web of Science (2017): Indexed yes
BFI (2016): BFI-level 1
Scopus rating (2016): CiteScore 5.25 SJR 2.461 SNIP 1.164
Web of Science (2016): Impact factor 5.314
Web of Science (2016): Indexed yes
BFI (2015): BFI-level 1
Scopus rating (2015): CiteScore 5.65 SJR 2.989 SNIP 1.301
Web of Science (2015): Impact factor 5.367
Web of Science (2015): Indexed yes
BFI (2014): BFI-level 1
Scopus rating (2014): CiteScore 5.3 SJR 2.991 SNIP 1.338
Web of Science (2014): Impact factor 5.331
BFI (2013): BFI-level 1
Scopus rating (2013): CiteScore 5.94 SJR 3.644 SNIP 1.415
Web of Science (2013): Impact factor 5.935
ISI indexed (2013): ISI indexed yes
Scopus rating (2012): CiteScore 5.59 SJR 3.325 SNIP 1.498
Web of Science (2012): Impact factor 6.701
ISI indexed (2012): ISI indexed yes